An immunological mechanism of resistance to CDK4/6 inhibitors in HR+ breast cancer
{{output}}
CDK4/6 inhibitors are central to the clinical management of HR+HER2- breast cancer. We have recently demonstrated that immunosuppressive, IL17-secreting γδ T cells recruited to the tumor microenvironment by a CCL2-dependent mechanism upon CDK4/6 inhibition c... ...
